Diabetes mellitus and hypertension are both major risk factors for cardiovascular morbidity and mortality. The coexistence of both diabetes and hypertension doubles the risk of cardiovascular events, cardiovascular mortality, and total mortality. 1, 2 The effect of different classes of antihypertensive drugs on incident diabetes mellitus has been described in a recent metaanalysis. 3 When compared to initial diuretic use, the relative risk reduction of diabetes was the highest for angiotensin receptor blockers, angiotensin-converting enzyme (ACE) inhibitors, and calcium-channel blockers (38%, 33%, and 21%, respectively). β-Blockers did not significantly change this risk.
Background
Variation in the renin-angiotensin system (RaS) and salt-sensitivity genes may influence the effect of thiazides on the risk of diabetes. We assessed whether polymorphisms in RaS and salt-sensitivity genes influenced the risk of diabetes associated with thiazides.
methodS
Nested case-control study was conducted among antihypertensive drug users. Pharmacy records and questionnaires were used to assess new onset diabetes (cases), to ascertain antihypertensive use and risk factors for diabetes. Cases were matched to controls (up to five) who were not (yet) diagnosed with diabetes mellitus. We genotyped angiotensin-converting enzyme (aCE) (G4656C), angiotensinogen (aGT) (M235T), angiotensin II type 1 receptor, (aGTR1) (a1166C), adducin 1 (alpha) (aDD1) (G460T), guanine nucleotide binding protein (G protein), β-polypeptide 3 (GNB3) (C825T). reSultS among 497 incident cases of type 2 diabetes and 2,633 controls, aGTR1 CC genotype carriers had no increased risk of diabetes due to thiazides (odds ratio (OR) 0.63 (95% confidence interval (CI): 0.28-1.40)) compared to aGTR1 1166a allele carriers (OR 1.79 (95% CI: 1.43-2.23)) receiving thiazides (synergy index (SI) for interaction 0.32 (95% CI: 0.15-0.68)). although homozygous aCE GG subjects and aCE C allele carriers both had an increased risk of diabetes associated with thiazide use, this risk was more increased for aCE GG subjects (SI 1.70 (95% CI: 1.08-2.66)), particularly at doses ≥1 daily defined dose (DDD) (=25 mg hydrochlorothiazide)/day (SI 2.0 (95% CI: 1.20-3.32)). among GNB3 T allele carriers, the risk of diabetes due to thiazide use was less increased than among homozygous GNB3 CC subjects (SI 0.62 (95% CI: 0.41-0.93)).
concluSion
The risk of diabetes due to thiazide use was not increased among aGTR1 1166 CC homozygous subjects and less increased among GNB3 T allele carriers. The aCE 4656 GG genotype enhanced the risk of diabetes due to thiazides.
articles Variation in Renin-Angiotensin System constitution) with more or less susceptibility to this side effect may help to identify strategies to prevent thiazide-induced diabetes as was recently acknowledged by a National Heart, Lung, and Blood Institute working group on thiazide-induced dysglycemia. 8 Genes involved in the RAS and salt-sensitivity system can be considered candidate genes for thiazide-induced type 2 diabetes mellitus. Whether variation in these candidate genes influences the response to thiazide diuretics with regard to the risk of diabetes is unknown. The study of interactions between genetic variation in candidate genes of thiazide diuretic response may eventually lead to an individualized treatment approach that determines which patients should be given diuretics and which patients not.
The aim of the present study was to assess whether the risk of diabetes associated with the use of thiazide diuretics was modified by variation in RAS and salt-sensitivity genes.
methodS
Design and setting. Among treated hypertensive patients, we performed a nested case-control study. Patients treated with antihypertensive drugs were identified from the PharmacoMorbidity Record Linkage System (PHARMO-RLS). PHARMO links drug dispensing histories from a representative sample of Dutch community pharmacies to the national registrations of hospital discharges (Landelijke Medische Registratie) from 1985 onwards. Currently, the base population of PHARMO covers about 2,000,000 community-dwelling inhabitants of about 50 population-defined areas in the Netherlands. Data from a pharmacogenetic study of antihypertensive drug treatment including 5,140 antihypertensive drug users were used to collect data on genotypes and potential risk factors for diabetes mellitus. In this pharmacogenetic study, specific genetic polymorphisms are examined with regard to antihypertensive drug response in a selection of PHARMO-RLS participants. 9 This study was approved by the Medical Ethical Committee of the University Medical Center Utrecht and all subjects have signed written informed consent.
Data collection. The PHARMO-RLS provides records containing the name of the dispensed drugs, day of dispensing, number of units dispensed, prescribed daily dose, and the anatomical therapeutical chemical code of the drug. Questionnaire information was used to collect data on demographic variables, cardiovascular diseases, and risk factors, whereas buccal swabs were used to collect DNA.
Outcome and exposure definition. The outcome of interest was incident diabetes. Pharmacy records were used to identify incident diabetes (cases). Incident cases of diabetes were defined as those having a first prescription for oral antidiabetic drugs or insulin at least 1 year after the date of entry in PHARMO-RLS. To assess the date of first diagnosis of diabetes mellitus, we used both pharmacy records and self-reported questionnaire information. All subjects reported on whether they had diabetes mellitus and on which date this was first diagnosed by a physician. Cases were assigned an index date, which was defined as either the date the first antidiabetic drug prescription was dispensed or the date of self-reported diagnosis of diabetes mellitus, whichever came first. For each case, we selected up to five controls who also received antihypertensive drugs but who were not (yet) diagnosed with diabetes mellitus at the index date of the case.
In a small validation study among 83 subjects for whom general practitioner records were available (24 cases and 59 controls), we found that 91.7% (22) of the cases could be confirmed according to World Health Organization criteria for a diagnosis of type 2 diabetes mellitus (either a fasting plasma glucose >7.0 mmol/l and/or random (nonfasting) blood glucose >11.1 mmol/l, and/or use of oral antidiabetic medication and/or use of insulin and/or treatment by diet and registered by a general practitioner as having type 2 diabetes mellitus), 10 whereas 100.0% (59) of the controls had no diagnosis of type 2 diabetes mellitus.
Exposure to antihypertensive drugs was ascertained from pharmacy records. All subjects were current users of at least one antihypertensive drug. Thiazide diuretic use was defined as current (at the index date) or not current (before the index date). We also calculated the dose of current use of thiazides according to the defined daily dose (DDD), which is the average daily dose of a drug for its main indication in adults, and is recommended by the World Health Organization for drug utilization studies. 11 For the diuretics that were used in our study, the DDDs were bendroflumethiazide (2.5 mg), hydrochlorothiazide (25 mg), chlorthiazide (25 mg), epitizide (4 mg), clopamide (10 mg), chlorthalidone (25 mg), mefruside (25 mg), and indapamide (2.5 mg).
Genotyping. Genomic DNA was isolated from buccal swabs according to standard procedures. Genotyping was determined using a multiplex single base extension method. Multiplex single base extension was performed using SNaPshot as described by the manufacturer (Applied Biosystems, Foster City, CA). This method was described earlier, 12 but adapted to a new set of polymorphisms for the pharmacogenetic study of antihypertensive drug therapy. The multiplex assay was validated on a set of 100 DNA samples that had previously been genotyped with an alternative technique; this technique concerned a multilocus genotyping assay for candidate markers of cardiovascular disease risk (Roche Molecular Systems, Basel, Switzerland) and has been described in detail previously. 13 The ACE (I/D) polymorphism was determined by detecting ACE4656+CT observed on the SNaPshot as ACE G4656C (NCBI singlenucleotide polymorphism (SNP) database nr: rs4341). The ACE4656+CT polymorphism in the 3′-untranslated region of the ACE gene consists of a repetition of two or three CT dinucleotides and is in complete linkage disequilibrium with ACE (I/D). 12, 14 The G detected on the SNaPshot corresponds with the deletion allele and the C corresponds with the insertion allele of the ACE gene. Furthermore, we assessed angiotensin II type 1 receptor (AGTR1) A1166C (NCBI SNP database: rs5186), angiotensinogen (AGT) Met235Thr (further denoted as M235T, NCBI SNP database nr: rs699), guanine nucleotide articles Variation in Renin-Angiotensin System binding protein (G protein), β-polypeptide 3 (GNB3) C825T (NCBI SNP database nr: rs5443), and adducin 1 (alpha) (ADD1) Gly460Trp (further denoted as G460T, NCBI SNP database nr: rs4961).
Analysis. Analysis was performed using SPSS (version 12.1, SPSS, Chicago, IL). Continuous variables are presented as mean ± s.d. Deviations from Hardy-Weinberg equilibrium were considered using chi-square tests. Unconditional logistic regression analysis was used to study the association between thiazide diuretic use and the incidence of new onset of diabetes. All analyses were stratified by ACE (G4656C), AGT (M235T), AGTR1 (A1166C), GNB3 (C825T), and ADD1 (G460T) genotype to study effect modification. We considered gender, smoking, physical activity, body mass index, alcohol use, calendar year, self-reported high blood pressure, and drug treated hypercholesterolemia as potential confounders.
Based on the results of preliminary analyses, we chose to combine homozygous and heterozygous 4656C allele carriers of the ACE gene, homozygous and heterozygous 1166A allele carriers of the AGTR1 gene, and homozygous and heterozygous 235T allele carriers of the AGT gene. These genotype groups showed similar effects of thiazides on the risk of diabetes. Because of small numbers of subjects, homozygous for the less common alleles of the GNB3 and ADD1 polymorphisms, these individuals were grouped together with heterozygotes.
To assess potential interactions, we estimated the odds ratio (OR) and confidence intervals for diabetes in strata defined by genotype. To test for drug-gene interaction, we computed the synergy index (SI) by adding an interaction term (THIAZIDE × GENOTYPE) to the logistic regression model. The SI can be interpreted as the ratio of the OR in subjects with a susceptible genotype and the OR in subjects without this genotype. A SI of 1 indicates no interaction on the multiplicative scale. 15 In sensitivity analyses, we also distinguished between thiazide diuretic use with or without a RAS inhibitor and thiazide diuretic use with or without a potassium sparing diuretic.
reSultS
Among 5,140 antihypertensive drug users, we identified 497 incident cases of type 2 diabetes mellitus and 2,633 controls. Table 1 shows the baseline characteristics of cases and controls.
The common risk factors for type 2 diabetes mellitus such as obesity, sedentary lifestyle, and hypercholesterolemia were significantly more common among cases than controls. Of the antihypertensive drugs studied, only the frequency of thiazide diuretic use differed significantly between cases and controls. Hydrochlorothiazide was the most frequently used thiazide diuretic, followed by indapamide and chlorthalidone.
Overall thiazide diuretic use was associated with an increased risk of diabetes mellitus in a dose-dependent way (OR <1 DDD/day 1.30 (95% confidence interval (CI): 0.95-1.77), OR ≥1 DDD/day 1.82 (95% CI: 1.43-2.31), see Table 2 , P for trend <0.001). For the largest groups of thiazide diuretics such as hydrochlorothiazide, epitizide, chlorthalidone, and indapamide the increased risk of diabetes mellitus was similar. The increased risk did not change when thiazides were used in combination with potassium sparing diuretics (adjusted OR 1.53 (95% CI: 1.05-2.23)) or in combination with RAS inhibitors (adjusted OR 1.70 (95%CI: 1.27-2.27)).
In the analysis stratified by polymorphisms in the RAS and salt-sensitivity genes, the dose dependent risk of diabetes due to thiazide use remained for all genotypes, except for the AGTR1 CC homozygotes ( Table 3) .
For the polymorphisms in the salt-sensitivity genes, ADD1 T allele carriers had a slightly higher risk of diabetes due to thiazide With regard to the polymorphisms in the RAS, both ACE 4656C allele carriers and ACE 4656 GG homozygotes had a significantly increased risk of developing diabetes while using thiazides (OR 1.38 (95% CI: 1.08-1.78) and 2.49 (95% CI: 1.65-3.75), respectively). However, carriers of the ACE GG genotype had a more increased risk while on thiazide therapy compared to C allele carriers (SI 1.70 (95% CI: 1.08-2.66), P = 0.022). This interaction was not present at doses <1 DDD/ day (SI 1.18 (95% CI: 0.58-2.38)), whereas among subjects who used thiazides at doses ≥1 DDD/day the interaction was strongest (SI 2.00 (95% CI: 1.20-3.32)).
Carriers of the AGTR1 1166 A allele had an increased risk of diabetes due to thiazide use (OR 1.79 (95% CI: 1.43-2.23)). Carriers of the AGTR1 CC genotype had no increased risk of diabetes while using thiazides (OR 0.63 (95% CI: 0.28-1.40)), not even at doses ≥1DDD/day (OR 0.57 (95% CI: 0.23-1.41)). The SI for the interaction between thiazide use and the AGTR1 CC genotype was 0.32 (95% CI: 0.15-0.68) (P = 0.003).
The AGT M235T polymorphism did not modify the association between thiazide use and diabetes mellitus.
In sensitivity analyses, we did not observe any influence of the combined use of thiazides and potassium sparing diuretics, nor of the combined use of thiazides and RAS inhibitors on the interaction between thiazides and the genetic polymorphisms of interest. We also studied the interaction between individual types of thiazide diuretics and found no major differences. The numbers for these analyses were quite small making definite inferences not possible. Finally, we also investigated all combinations of two genes. None of these combinations resulted in statistically significantly interactions with thiazide diuretic use.
diScuSSion
Our study suggests that the risk of diabetes associated with the use of thiazides is strongly modified by the GNB3 C825T, ACE G4656C, and AGTR1 A1166C polymorphisms. Carriers of the ACE 4656 GG genotype were most susceptible to the detrimental effect of thiazides on the risk of diabetes, whereas carriers of the AGTR1 CC genotype had no increased risk of diabetes and carriers of the GNB3 825T allele who used thiazides had a less increased risk of diabetes. The increased susceptibility of ACE 4656 GG homozygote subjects to the effect of thiazides on the risk of diabetes was only present among subjects who used doses ≥1 DDD/day.
The strengths of this observational study are the relatively large sample size and the complete and accurate information on drug exposure and most risk factors that are important when considering possible antihypertensive drug-gene interactions. The limitations of our study are first of all our case definition that was based on the use of glucose lowering medication and the use of self-reported information on diagnosis dates. This method may have lead to a misclassification of cases and controls. Our small validation study however showed that our case definition was highly accurate compared to diagnostic information from general practitioner records. Second, we did not have information on serum potassium levels. The review by Zillich et al. showed that the 16 Nonetheless, in this study no differences in potassium levels were observed between chlorthalidone and hydrochlorothiazide. Therefore, in our study on the risk of diabetes mellitus the use of the DDD for dose-response relationships was appropriate. Fourth, a limitation of this study is that despite almost complete information on important potential confounders, we cannot fully exclude residual confounding due to unmeasured or inaccurately measured factors.
Fifth, our study was restricted to only one polymorphism per gene, although the polymorphisms were selected because of a biologically plausible role in response to thiazides. Finally, although the sample size of our study was relatively large, it was too small to assess drug-gene-gene interactions and to assess the effect of potassium sparing agents. When a more stringent significance level of 0.01 would have been applied, only the interaction between AGTR1 and thiazides remained significant. Therefore, our findings should be considered as hypothesis generating and need replication in other studies. To our knowledge, this is the first study that investigated the influence of variation in RAS genes and salt-sensitivity genes on the risk of diabetes associated with thiazide use.
One might speculate on explanations for our findings. On the one hand, one could entertain the hypothesis that genotypes that may be related to an increased RAS activity (ACE GG genotype, AGTR1 CC genotype, and AGT T allele) would be associated with a smaller response to thiazide diuretics (more counterregulation, less potassium excretion, and smaller risk of diabetes). 17 However, on the other hand, increased activation of the RAS due to thiazides among subjects with a genetically already increased RAS activity might further increase angiotensin II signaling, which diminishes insulin signaling and glucose transport and thereby increase the risk of diabetes. [18] [19] [20] Our finding that carriers of the ACE GG genotype (which corresponds to the DD genotype of the ACE insertion/deletion polymorphism) had a twofold increased risk of developing diabetes while receiving thiazide diuretics in doses ≥1 DDD compared to C allele carries (I allele) suggests that the deleterious effects of increased RAS activity on glucose metabolism might be the dominating mechanism. However, the AGTR1 CC genotype that is associated with a greater sensitivity for angiotensin-II through a greater number of receptor binding sites and affinity for angiotensin-II 21 was associated with a reduced risk of diabetes due to thiazides. This finding suggests that more counterregulation of the thiazide induced sodium-volume depletion and related potassium excretion might explain the reduced risk of diabetes among these subjects. The sample size of our study was not large enough to investigate whether the ACE G4656C or the AGTR1 A1166C polymorphism is more important in determining the effect of thiazides on the risk of diabetes.
The GNB3 825T allele has been associated with an increased blood pressure response to thiazide diuretic therapy. 22 Interestingly, in a small trial the GNB3 825T allele was not associated with increased thiazide-induced potassium excretion, 23 whereas in another trial the 825T allele was associated with a greater angiotensin-II responsiveness. 24 These experimental findings would suggest that a greater RAS activity of GNB3 825T allele carriers may result in a stronger counterregulation of thiazide induced volume depletion and related potassium excretion. This increased potassium excretion probably explains the lower risk of thiazide induced diabetes among GNB3 825T allele carriers. Increased potassium excretion resulting in hypokalemia increase glucose levels and probably the risk of type 2 diabetes mellitus as was suggested by the National Heart, Lung, and Blood Institute working group on thiazide-induced dysglycemia and further supported by the analysis of Zillich et al. 7, 8 Moreover, Shafi et al. demonstrated in a post hoc analysis of the Systolic Hypertension in the Elderly Program trial comparing chlorthalidone with placebo that the risk of diabetes was mediated for about 41% by decreased serum potassium levels. 25 Although our findings need confirmation in other studies, in the future an individualized treatment approach in which the choice for thiazide diuretic therapy depends on the genotype of a patient might be feasible. To appreciate the potential impact of a genotype-based treatment with thiazides, we calculated the number of diabetes mellitus patients that might be prevented if for instance only subjects with the GNB3 T allele would be given thiazides and that homozygous wild type subjects would be given other antihypertensive agents. Based on an absolute risk of incident diabetes mellitus of about 6.8% during an average follow-up of approximately 3-4 years in the placebo groups of randomized controlled trials of antihypertensive drug treatment, a prevalence of the GNB3 T allele of 69%, this strategy would prevent about 25 cases of diabetes mellitus for every 1,000 patients who were going to be treated with thiazide diuretics. In an overall treatment strategy, the beneficial effects of thiazides on the risk of cardiovascular disease should be weighed against side effects such as an increased risk of diabetes mellitus.
In conclusion, the risk of diabetes associated with the use of thiazide diuretics in hypertensive subjects was modified by polymorphisms in the RAS and one salt-sensitivity gene. Carriers of the AGTR1 1166 CC had a significantly lower risk of diabetes compared to A allele carriers, while carriers of the ACE 4656 GG genotype who used thiazides at doses ≥1 DDD/ day had a significantly higher risk of diabetes compared to C allele carriers. GNB3 T allele carriers of the C825T polymorphism had a significantly decreased risk of diabetes due to thiazides compared to CC genotype carriers. 
